{"id":"NCT01628107","sponsor":"Pfizer","briefTitle":"A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin","officialTitle":"A Phase III, Open-label, Multicenter, Long-term Safety Study Of Intravenous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07-16","primaryCompletion":"2015-01-02","completion":"2015-01-02","firstPosted":"2012-06-26","resultsPosted":"2018-07-19","lastUpdate":"2018-07-19"},"enrollment":406,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Renal Failure Requiring Hemodialysis"],"interventions":[{"type":"BIOLOGICAL","name":"Epoetin Hospira","otherNames":["ESA","Erythropoetin Stimulating Agent"]}],"arms":[{"label":"Epoetin Hospira","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to determine the long-term safety in treatment-emergent adverse events (TEAEs) of intravenous (IV) administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.","primaryOutcome":{"measure":"Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1","timeFrame":"Up through 7 days after first dose of study drug (Week 1)","effectByArm":[{"arm":"Epoetin Hospira","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":110,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["32734207"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":168,"n":406},"commonTop":["Muscle spasms","Nausea","Headache","Diarrhoea","Dizziness"]}}